 |
|
Selective Antidepressants and Cerebrospinal FluidLack of Specificity on Norepinephrine and Serotonin Metabolites
William Z. Potter, MD, PhD;
Mika Scheinin, MD, PhD;
Robert N. Golden, MD;
Matthew V. Rudorfer, MD;
Rex W. Cowdry, MD;
Helena M. Calil, MD, PhD;
Richard J. Ross, MD, PhD;
Markku Linnoila, MD, PhD
Arch Gen Psychiatry. 1985;42(12):1171-1177.
Abstract
• Cerebrospinal fluid concentrations of the norepinephrine metabolite, 3-methoxy-4-hydroxyphenylglycol (MHPG), the serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), and the dopamine metabolite, homovanillic acid, were measured in depressed patients before and after treatment with three putatively specific antidepressants. The expected specificity of action on these three neurotransmitter metabolites was not observed. Desipramine hydrochloride, a norepinephrine uptake inhibitor, reduced 5-HIAA as well as MHPG concentrations; zimeldine hydrochloride, a serotonin uptake inhibitor, reduced MHPG as well as 5-HIAA concentrations; and clorgyline, a selective monoamine oxidase type A inhibitor, which might be predicted to most affect 5-HIAA, dramatically reduced MHPG, moderately reduced homovanillic acid, and only modestly reduced 5-HIAA concentrations.
Author Affiliations
From the Section on Clinical Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Md.
Footnotes
Accepted for publication Oct 18, 1984.
Reprint requests to Section on Clinical Psychopharmacology, Laboratory of Clinical Science, National Institute of Mental Health, Bldg 10, Room 2D46, Bethesda, MD 20205 (Dr Potter).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Endocrine Withdrawal Syndromes
Hochberg et al.
Endocr. Rev. 2003;24:523-538.
ABSTRACT
| FULL TEXT
Effects of Exposure to Selective Serotonin Reuptake Inhibitors During Pregnancy on Serotonergic Symptoms in Newborns and Cord Blood Monoamine and Prolactin Concentrations
Laine et al.
Arch Gen Psychiatry 2003;60:720-726.
ABSTRACT
| FULL TEXT
Inhibition of Norepinephrine Uptake in Patients With Major Depression Treated With Paroxetine
Gilmor et al.
Am. J. Psychiatry 2002;159:1702-1710.
ABSTRACT
| FULL TEXT
Changes in Cerebrospinal Fluid Neurochemistry During Treatment of Obsessive-compulsive Disorder With Clomipramine
Altemus et al.
Arch Gen Psychiatry 1994;51:794-803.
ABSTRACT
The Mechanisms of Action of Lithium: II. Effects on Adenylate Cyclase Activity and {beta}-Adrenergic Receptor Binding in Normal Subjects
Risby et al.
Arch Gen Psychiatry 1991;48:513-524.
ABSTRACT
Psychology and pharmacology in the treatment of anxiety disorders: co-operation or confrontation
Middleton
J Psychopharmacol 1991;5:281-285.
ABSTRACT
'Psychological inflammation'. Clarification of the model and a rejoinder
Middleton
J Psychopharmacol 1991;5:301-304.
Memory Improvement in Korsakoff's Disease With Fluvoxamine-Reply
Martin et al.
Arch Gen Psychiatry 1990;47:978-979.
ABSTRACT
Specificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder: Comparison of Fluvoxamine and Desipramine
Goodman et al.
Arch Gen Psychiatry 1990;47:577-585.
ABSTRACT
Effects of Renal Clearance on Plasma Concentrations of Homovanillic Acid: Methodologic Cautions
Potter et al.
Arch Gen Psychiatry 1989;46:558-562.
ABSTRACT
Bupropion in Depression: I. Biochemical Effects and Clinical Response
Golden et al.
Arch Gen Psychiatry 1988;45:139-143.
ABSTRACT
Monoamine Neurotransmitter Interactions and the Prediction of Antidepressant Response
Hsiao et al.
Arch Gen Psychiatry 1987;44:1078-1083.
ABSTRACT
Afternoon Continuous Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol and Age: Distinctive Biologic Subgroups of Endogenous Depression?
Halbreich et al.
Arch Gen Psychiatry 1987;44:804-812.
ABSTRACT
|
